Afuco™ Anti-MS4A1 ADCC Therapeutic Antibody (Obinutuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human MS4A1. Obinutuzumab was approved under the tradename obinutuzumab by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-H51 |
| Pricing | Inquiry |
| Host | Human |
| Target | MS4A1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | ELISA, FC, IP, FuncS, IF, Neut |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |